The state of having multiple leiomyomas throughout the body. (Stedman, 25th ed)
An enzyme that catalyzes the reversible hydration of fumaric acid to yield L-malic acid. It is one of the citric acid cycle enzymes. EC 4.2.1.2.
Tumors or cancer of the UTERUS.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.
Surgical removal of a LEIOMYOMA of the UTERUS.
The condition of a pattern of malignancies within a family, but not every individual's necessarily having the same neoplasm. Characteristically the tumor tends to occur at an earlier than average age, individuals may have more than one primary tumor, the tumors may be multicentric, usually more than 25 percent of the individuals in direct lineal descent from the proband are affected, and the cancer predisposition in these families behaves as an autosomal dominant trait with about 60 percent penetrance.
A name applied to several itchy skin eruptions of unknown cause. The characteristic course is the formation of a dome-shaped papule with a small transient vesicle on top, followed by crusting over or lichenification. (From Dorland, 27th ed)
The venous trunk which receives blood from the lower extremities and from the pelvic and abdominal organs.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
Tumors or cancers of the KIDNEY.
A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)
Twisting of the STOMACH that may result in gastric ISCHEMIA and GASTRIC OUTLET OBSTRUCTION. It is often associated with DIAPHRAGMATIC HERNIA.
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
A group of inherited conditions characterized initially by HEMATURIA and slowly progressing to RENAL INSUFFICIENCY. The most common form is the Alport syndrome (hereditary nephritis with HEARING LOSS) which is caused by mutations in genes for TYPE IV COLLAGEN and defective GLOMERULAR BASEMENT MEMBRANE.
Tumors or cancer of the PERITONEUM.
Surgery performed on the female genitalia.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY. If appropriate, biopsy or surgery can be performed during laparoscopy.
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).
An abnormal anatomical passage that connects the VAGINA to other organs, such as the bladder (VESICOVAGINAL FISTULA) or the rectum (RECTOVAGINAL FISTULA).
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
An opioid analgesic chemically related to and with an action resembling that of MEPERIDINE, but more rapid in onset and of shorter duration. It has been used in obstetrics, as pre-operative medication, for minor surgical procedures, and for dental procedures. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1067)

Absence of the alpha6(IV) chain of collagen type IV in Alport syndrome is related to a failure at the protein assembly level and does not result in diffuse leiomyomatosis. (1/113)

X-linked Alport syndrome is a progressive nephropathy associated with mutations in the COL4A5 gene. The kidney usually lacks the alpha3-alpha6 chains of collagen type IV, although each is coded by a separate gene. The molecular basis for this loss remains unclear. In canine X-linked hereditary nephritis, a model for X-linked Alport syndrome, a COL4A5 mutation results in reduced mRNA levels for the alpha3, alpha4, and alpha5 chains in the kidney, implying a mechanism coordinating the production of these 3 chains. To examine whether production of alpha6 chain is under the same control, we studied smooth muscle cells from this animal model. We determined the canine COL4A5 and COL4A6 genes are separated by 435 bp, with two first exons for COL4A6 separated by 978 bp. These two regions are >/= 78% identical to the human sequences that have promoter activity. Despite this potential basis for coordinated transcription of the COL4A5 and COL4A6 genes, the alpha6 mRNA level remained normal in affected male dog smooth muscle while the alpha5 mRNA level was markedly reduced. However, both alpha5 and alpha6 chains were absent at the protein level. Our results suggest that production of the alpha6 chain is under a control mechanism separate from that coordinating the alpha3-alpha5 chains and that the lack of the alpha6 chain in Alport syndrome is related to a failure at the protein assembly level, raising the possibility that the alpha5 and alpha6 chains are present in the same network. The lack of the alpha6 chain does not obviously result in disease, in particular leiomyomatosis, as is seen in Alport patients with deletions involving the COL4A5 and COL4A6 genes.  (+info)

Human uterine leiomyomata express higher levels of peroxisome proliferator-activated receptor gamma, retinoid X receptor alpha, and all-trans retinoic acid than myometrium. (2/113)

Uterine leiomyomata are the main indication for a hysterectomy in the United States and occur in 25% of women >35 years. Because uterine leiomyomata can form when ovariectomized guinea pigs are exposed to estradiol and retinoic acids, we tested whether human leiomyomata had high levels of retinoic acids and related nuclear receptors. Compared with normal human myometrium, leiomyomata had 3- to 5-fold higher levels of peroxisome proliferator-activated receptor gamma (PPARgamma), retinoid X receptor alpha proteins, and all-trans retinoic acid, but only during the follicular phase of the menstrual cycle. 9-cis Retinoic acid was undetectable in either leiomyomata or myometrium. PPARgamma mRNA levels were lower in leiomyomata than myometrium, but only during the luteal phase of the cycle. A PPARgamma agonist, troglitazone, was given to guinea pigs along with estradiol and all-trans retinoic acid and produced the largest leiomyomata seen to date in this model. By contrast, no tumors formed when troglitazone was given alone or with estradiol or when troglitazone was given with estradiol and 9-cis retinoic acid. New therapies for human leiomyomata may emerge by combining antagonists for PPARgamma and retinoid X receptor alpha with selective estrogen receptor modulators.  (+info)

Unusual abdominal tumors with intracardiac extension. Two cases with successful surgical resection. (3/113)

Abdominal tumors that can grow through vascular lumen and spread to the right heart are rare. Although these tumors have different histologic aspects, they may cause similar abdominal and cardiac symptoms and are a serious risk factor for pulmonary embolism and sudden death when they reach the right atrium and tricuspid valve. The best treatment is radical surgical resection of the entire tumor using cardiopulmonary bypass with or without deep hypothermia and total circulatory arrest. We report the cases of two patients, the first with leiomyosarcoma of the inferior vena cava and the other with intravenous leiomyomatosis of the uterus that showed intravascular growth up to right atrium and ventricle, who underwent successful radical resection in a one-stage procedure with the use of cardiopulmonary bypass. We discuss the clinical and histologic aspects and imaging diagnosis and review the literature.  (+info)

Intravenous leiomyomatosis with cardiac extension: tumor thrombectomy through an abdominal approach. (4/113)

Intravenous leiomyomatosis is an uncommon vascular tumor that may be seen with potentially life-threatening symptoms resulting from intracardiac extension. This tumor is frequently misdiagnosed and treated without appropriate preoperative imaging and planning, which at times leads to inadequate treatment and incomplete resections. The appropriate therapy is complete excision of the tumor. We describe a patient who was treated with a new approach involving a single-stage operation without the need for median sternotomy, cardiopulmonary bypass graft, or hypothermic arrest by resection of the tumor from the point of attachment in the abdominal portion of the inferior vena cava.  (+info)

Laparoscopic myomectomy: a current view. (5/113)

Since 1990 laparoscopic myomectomy (LM) has provided an alternative to laparotomy when intramural and subserous myomata are to be managed surgically. However, this technique is still the subject of debate. Based on their own experience together with data from the literature, the authors report on the situation today regarding the operative technique for LM and the risks and benefits of the technique as compared with myomectomy by laparotomy. The operative technique comprises four main phases: hysterotomy; enucleation; suture of the myomectomy site and extraction of the myoma. LM offers the possibility of a minimally invasive approach to treat medium-sized (<9 cm) subserous and intramural myomata by surgery when there are only two or three of them. When conducted by experienced surgeons, the risk of peri-operative complications is no higher using this technique. Use of the laparoscopic route could reduce the haemorrhagic risk associated with myomectomy. LM could reduce also the risk of post-operative adhesions as compared with laparotomy. Spontaneous uterine rupture seems to be rare after LM but further studies are needed before it can be said whether the strength of the hysterotomy scars after LM is equivalent to that obtained after laparotomy. The risk of recurrence seems to be higher after LM than after myomectomy performed by laparotomy.  (+info)

Recurrence of leiomyomata after myomectomy. (6/113)

Abdominal myomectomy (by laparotomy or by laparoscopy) enables all the myomata to be excised while maintaining reproductive function. The actual risk of recurrence after abdominal myomectomy is difficult to assess because of methodological problems. Studies using life-table analysis find a cumulative risk of clinically significant recurrence of approximately 10% at 5 years for myomectomy by laparotomy. This risk probably underestimates the true prevalence of myomata as assessed by systematic ultrasound investigation. After laparoscopic myomectomy there appears to be a greater risk of recurrence. In one third of cases, recurrence becomes the reason for a hysterectomy. The risk of recurrence increases when there is more than one myoma. The use of gonadotrophin-releasing hormone agonists preoperatively could increase the risk of recurrence. Persistence or recurrence of the myoma thus reduces the chances of conception or taking a pregnancy full term after the myomectomy. It is essential to obtain the most complete exeresis possible in order to reduce the risk of recurrence to a minimum. However, it is inevitable that small, undetectable nuclei will remain within the myometrium whatever approach is used (laparoscopy or laparotomy). It would be an advantage to know what the growth factors are and how to identify groups at high risk of recurrence so that the treatment strategies could be better adapted and appropriate prophylactic methods developed.  (+info)

Embolization of uterine leiomyomata: current concepts in management. (7/113)

Transcatheter bilateral uterine artery embolization is a relatively new, but fast increasing modality being offered as an alternative to surgery for the treatment of symptomatic uterine fibroids (myomata). Since its introduction in 1995, it is estimated that over 5000 procedures have been performed, despite little objective evidence of its efficacy in comparison with more traditional surgical procedures, e.g. hysterectomy, abdominal or laparoscopic myomectomy or hysteroscopic procedures. The enthusiastic uptake of uterine artery embolization is partly due to the fact that it can be performed as a day case, and is a means of avoiding surgery especially hysterectomy. However, the procedure is not without significant risks, and these are becoming clearer as more procedures are being reported. This review examines the procedure, its use and purported efficacy and discusses its complications and potential hazards.  (+info)

Laparoscopic myolysis. (8/113)

This review will focus on the different techniques and the long-term effects of the technique called myolysis on myoma growth. Indications for myolysis are essentially pelvic pain, compression symptoms and global uterine volume in order to avoid hysterectomy. In the late 1980s, myolysis was performed laparoscopically with the help of the neodynium: yttrium aluminium garnet (Nd:YAG) laser. Later, bipolar needles were developed as an alternative to the Nd:YAG laser. Diathermy and cryomyolysis were also proposed but series are small in the literature. Very recently, myoma interstitial thermo-therapy (MITT) was performed using the diode laser and a specific optical light diffuser that is designed to transmit laser light in all directions. Laparoscopic myolysis was proved to be effective in provoking myoma shrinkage, with a dramatic decrease in size and a marked devascularization of the myoma and this technique can be proposed as an alternative to myomectomy in selected patients: only those aged >40 years or those not desiring to bear any more children.  (+info)

Leiomyomatosis is a medical term that refers to the benign growth (non-cancerous) of smooth muscle cells, which form tumors known as leiomyomas or fibroids. These growths can occur in various parts of the body, including the skin, uterus, gastrointestinal tract, and other organs.

The term "leiomyomatosis" is often used to describe a condition where multiple smooth muscle tumors develop in a single organ or throughout the body. For example:

1. Cutaneous leiomyomatosis - Multiple benign tumors of the smooth muscle in the skin.
2. Uterine leiomyomatosis - Multiple fibroids in the uterus, also known as uterine fibroids or myomas.
3. Gastrointestinal stromal tumor (GIST) leiomyomatosis - Multiple benign smooth muscle tumors in the gastrointestinal tract.
4. Disseminated peritoneal leiomyomatosis - Multiple benign smooth muscle tumors spread across the peritoneum, the lining of the abdominal cavity.

These conditions are usually not cancerous but can cause various symptoms depending on their location and size. Treatment options may include surveillance, medication, or surgical removal of the tumors.

Fumarate hydratase (FH) is an enzyme that plays a crucial role in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. The citric acid cycle is a series of chemical reactions used by all living cells to generate energy through the oxidation of acetyl-CoA derived from carbohydrates, fats, and proteins into adenosine triphosphate (ATP), carbon dioxide, and water.

Fumarate hydratase is specifically responsible for catalyzing the conversion of fumarate to malate in this cycle. A deficiency or dysfunction of this enzyme can lead to various metabolic disorders and hereditary diseases, such as fumarate hydratase deficiency, which may manifest as neurological issues, hemolytic anemia, and an increased risk of developing renal cell carcinoma.

Uterine neoplasms refer to abnormal growths in the uterus, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from different types of cells within the uterus, leading to various types of uterine neoplasms. The two main categories of uterine neoplasms are endometrial neoplasms and uterine sarcomas.

Endometrial neoplasms develop from the endometrium, which is the inner lining of the uterus. Most endometrial neoplasms are classified as endometrioid adenocarcinomas, arising from glandular cells in the endometrium. Other types include serous carcinoma, clear cell carcinoma, and mucinous carcinoma.

Uterine sarcomas, on the other hand, are less common and originate from the connective tissue (stroma) or muscle (myometrium) of the uterus. Uterine sarcomas can be further divided into several subtypes, such as leiomyosarcoma, endometrial stromal sarcoma, and undifferentiated uterine sarcoma.

Uterine neoplasms can cause various symptoms, including abnormal vaginal bleeding or discharge, pelvic pain, and difficulty urinating or having bowel movements. The diagnosis typically involves a combination of imaging tests (such as ultrasound, CT, or MRI scans) and tissue biopsies to determine the type and extent of the neoplasm. Treatment options depend on the type, stage, and patient's overall health but may include surgery, radiation therapy, chemotherapy, or hormone therapy.

Vascular neoplasms are a type of tumor that develops from cells that line the blood vessels or lymphatic vessels. These tumors can be benign (non-cancerous) or malignant (cancerous). Benign vascular neoplasms, such as hemangiomas and lymphangiomas, are usually harmless and may not require treatment unless they cause symptoms or complications. Malignant vascular neoplasms, on the other hand, are known as angiosarcomas and can be aggressive, spreading to other parts of the body and potentially causing serious health problems.

Angiosarcomas can develop in any part of the body but are most commonly found in the skin, particularly in areas exposed to radiation or chronic lymph edema. They can also occur in the breast, liver, spleen, and heart. Treatment for vascular neoplasms depends on the type, location, size, and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Leiomyoma is a benign (non-cancerous) tumor that originates from the smooth muscle cells. It most commonly occurs in the uterus, where it is also known as a fibroid, but can also develop in other parts of the body such as the skin, gastrointestinal tract, and genitourinary system. Leiomyomas are typically slow-growing and often cause no symptoms, although they can lead to various complications depending on their size and location. Treatment options for leiomyomas include surveillance, medication, or surgical removal.

A uterine myomectomy is a surgical procedure that involves removing uterine fibroids, which are noncancerous growths that develop in the muscular wall of the uterus. The surgery aims to preserve the uterus, unlike a hysterectomy, where the entire uterus is removed.

During the myomectomy procedure, the surgeon makes an incision in the uterus, carefully extracts the fibroids, and then closes the incision. The approach to the surgery can vary depending on factors such as the size, number, and location of the fibroids:

1. Abdominal myomectomy: An open surgical procedure where an incision is made in the lower abdomen to access the uterus directly. This method is typically used when there are numerous or large fibroids.
2. Laparoscopic myomectomy: A minimally invasive procedure that involves making several small incisions in the abdomen, through which a laparoscope (a thin, lighted tube with a camera) and specialized surgical instruments are inserted to perform the surgery. This method is often preferred for smaller fibroids and when preserving the uterus is essential.
3. Hysteroscopic myomectomy: Another minimally invasive procedure that involves inserting a hysteroscope through the cervix into the uterine cavity to remove submucosal fibroids (fibroids that grow into the inner cavity of the uterus). No abdominal incisions are required for this approach.

Recovery time and postoperative discomfort will vary depending on the type of myomectomy performed, but generally, minimally invasive procedures result in quicker recoveries and fewer complications compared to open surgeries.

Hereditary neoplastic syndromes refer to genetic disorders that predispose affected individuals to develop tumors or cancers. These syndromes are caused by inherited mutations in specific genes that regulate cell growth and division. As a result, cells may divide and grow uncontrollably, leading to the formation of benign or malignant tumors.

Examples of hereditary neoplastic syndromes include:

1. Hereditary breast and ovarian cancer syndrome (HBOC): This syndrome is caused by mutations in the BRCA1 or BRCA2 genes, which increase the risk of developing breast, ovarian, and other cancers.
2. Lynch syndrome: Also known as hereditary non-polyposis colorectal cancer (HNPCC), this syndrome is caused by mutations in DNA mismatch repair genes, leading to an increased risk of colon, endometrial, and other cancers.
3. Li-Fraumeni syndrome: This syndrome is caused by mutations in the TP53 gene, which increases the risk of developing a wide range of cancers, including breast, brain, and soft tissue sarcomas.
4. Familial adenomatous polyposis (FAP): This syndrome is caused by mutations in the APC gene, leading to the development of numerous colon polyps that can become cancerous if not removed.
5. Neurofibromatosis type 1 (NF1): This syndrome is caused by mutations in the NF1 gene and is characterized by the development of benign tumors called neurofibromas on the nerves and skin.
6. Von Hippel-Lindau disease (VHL): This syndrome is caused by mutations in the VHL gene, leading to an increased risk of developing various types of tumors, including kidney, pancreas, and adrenal gland tumors.

Individuals with hereditary neoplastic syndromes often have a higher risk of developing cancer than the general population, and they may require more frequent screening and surveillance to detect cancers at an early stage when they are more treatable.

Prurigo is a dermatological condition characterized by the development of persistent, itchy papules (small, solid, raised bumps) on the skin. These lesions often result in scratching or rubbing, which can further exacerbate the itching and lead to the formation of new papules. The exact cause of prurigo is not well understood, but it may be associated with various underlying conditions such as atopic dermatitis, diabetes, HIV infection, or chronic renal failure.

There are two main types of prurigo: acute and chronic. Acute prurigo typically lasts for less than six months and is often triggered by an insect bite, drug reaction, or other short-term factors. Chronic prurigo, on the other hand, can persist for years and may be more resistant to treatment.

Prurigo can significantly affect a person's quality of life due to constant itching, discomfort, and potential sleep disturbances. Dermatological evaluation, identification of underlying causes, and appropriate management strategies are essential in addressing this condition effectively.

The inferior vena cava (IVC) is the largest vein in the human body that carries deoxygenated blood from the lower extremities, pelvis, and abdomen to the right atrium of the heart. It is formed by the union of the left and right common iliac veins at the level of the fifth lumbar vertebra. The inferior vena cava is a retroperitoneal structure, meaning it lies behind the peritoneum, the lining that covers the abdominal cavity. It ascends through the posterior abdominal wall and passes through the central tendon of the diaphragm to enter the thoracic cavity.

The inferior vena cava is composed of three parts:

1. The infrarenal portion, which lies below the renal veins
2. The renal portion, which receives blood from the renal veins
3. The suprahepatic portion, which lies above the liver and receives blood from the hepatic veins before draining into the right atrium of the heart.

The inferior vena cava plays a crucial role in maintaining venous return to the heart and contributing to cardiovascular function.

Heart neoplasms are abnormal growths or tumors that develop within the heart tissue. They can be benign (noncancerous) or malignant (cancerous). Benign tumors, such as myxomas and rhabdomyomas, are typically slower growing and less likely to spread, but they can still cause serious complications if they obstruct blood flow or damage heart valves. Malignant tumors, such as angiosarcomas and rhabdomyosarcomas, are fast-growing and have a higher risk of spreading to other parts of the body. Symptoms of heart neoplasms can include shortness of breath, chest pain, fatigue, and irregular heart rhythms. Treatment options depend on the type, size, and location of the tumor, and may include surgery, radiation therapy, or chemotherapy.

Kidney neoplasms refer to abnormal growths or tumors in the kidney tissues that can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various types of kidney cells, including the renal tubules, glomeruli, and the renal pelvis.

Malignant kidney neoplasms are also known as kidney cancers, with renal cell carcinoma being the most common type. Benign kidney neoplasms include renal adenomas, oncocytomas, and angiomyolipomas. While benign neoplasms are generally not life-threatening, they can still cause problems if they grow large enough to compromise kidney function or if they undergo malignant transformation.

Early detection and appropriate management of kidney neoplasms are crucial for improving patient outcomes and overall prognosis. Regular medical check-ups, imaging studies, and urinalysis can help in the early identification of these growths, allowing for timely intervention and treatment.

Leiomyosarcoma is a type of cancer that arises from the smooth muscle cells, which are responsible for the involuntary contractions of various organs and blood vessels. It most commonly occurs in the uterus, soft tissues (such as muscles and fat), and the gastrointestinal tract.

Leiomyosarcomas can vary in their aggressiveness and may spread to other parts of the body (metastasize) through the bloodstream or lymphatic system. The prognosis for leiomyosarcoma depends on several factors, including the location and size of the tumor, the patient's age and overall health, and the extent of metastasis. Treatment typically involves surgical removal of the tumor, along with radiation therapy and/or chemotherapy to help prevent recurrence or spread of the cancer.

Stomach volvulus is a medical condition that involves the twisting or rotation of the stomach around its axis, leading to obstruction of the inflow and outflow of the stomach. This can result in strangulation of the blood supply to the stomach wall, potentially causing ischemia, necrosis, and perforation if not promptly treated. It is a surgical emergency that requires immediate medical attention. The condition can be congenital or acquired, with the acquired form being more common and often associated with underlying conditions such as gastric distention, laxity of gastrocolic ligaments, or previous abdominal surgery.

Carcinoma, renal cell (also known as renal cell carcinoma or RCC) is a type of cancer that originates in the lining of the tubules of the kidney. These tubules are small structures within the kidney that help filter waste and fluids from the blood to form urine.

Renal cell carcinoma is the most common type of kidney cancer in adults, accounting for about 80-85% of all cases. It can affect people of any age, but it is more commonly diagnosed in those over the age of 50.

There are several subtypes of renal cell carcinoma, including clear cell, papillary, chromophobe, and collecting duct carcinomas, among others. Each subtype has a different appearance under the microscope and may have a different prognosis and response to treatment.

Symptoms of renal cell carcinoma can vary but may include blood in the urine, flank pain, a lump or mass in the abdomen, unexplained weight loss, fatigue, and fever. Treatment options for renal cell carcinoma depend on the stage and grade of the cancer, as well as the patient's overall health and preferences. Treatment may include surgery, radiation therapy, chemotherapy, immunotherapy, or targeted therapy.

Hereditary nephritis is a genetic disorder that causes recurring inflammation of the kidneys' glomeruli, which are the tiny blood vessel clusters that filter waste from the blood. This condition is also known as hereditary glomerulonephritis.

The inherited form of nephritis is caused by mutations in specific genes, leading to abnormalities in the proteins responsible for maintaining the structural integrity and proper functioning of the glomeruli. As a result, affected individuals typically experience hematuria (blood in urine), proteinuria (protein in urine), hypertension (high blood pressure), and progressive kidney dysfunction that can ultimately lead to end-stage renal disease (ESRD).

There are different types of hereditary nephritis, such as Alport syndrome and thin basement membrane nephropathy. These conditions have distinct genetic causes, clinical presentations, and inheritance patterns. Early diagnosis and appropriate management can help slow the progression of kidney damage and improve long-term outcomes for affected individuals.

Peritoneal neoplasms refer to tumors or cancerous growths that develop in the peritoneum, which is the thin, transparent membrane that lines the inner wall of the abdomen and covers the organs within it. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Malignant peritoneal neoplasms are often associated with advanced stages of gastrointestinal, ovarian, or uterine cancers and can spread (metastasize) to other parts of the abdomen.

Peritoneal neoplasms can cause various symptoms such as abdominal pain, bloating, nausea, vomiting, loss of appetite, and weight loss. Diagnosis typically involves imaging tests like CT scans or MRIs, followed by a biopsy to confirm the presence of cancerous cells. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these approaches, depending on the type, stage, and location of the neoplasm.

Gynecologic surgical procedures refer to the operations that are performed on the female reproductive system and related organs. These surgeries can be either minimally invasive or open procedures, depending on the condition and the patient's health status.

The indications for gynecologic surgical procedures may include but are not limited to:

1. Diagnosis and treatment of various benign and malignant conditions such as uterine fibroids, ovarian cysts, endometriosis, and cancers of the reproductive organs.
2. Management of abnormal uterine bleeding, pelvic pain, and infertility.
3. Treatment of ectopic pregnancies and miscarriages.
4. Pelvic organ prolapse repair.
5. Sterilization procedures such as tubal ligation.
6. Investigation and treatment of suspicious lesions or abnormal Pap smears.

Some common gynecologic surgical procedures include hysterectomy (removal of the uterus), oophorectomy (removal of the ovary), salpingectomy (removal of the fallopian tube), cystectomy (removal of a cyst), myomectomy (removal of fibroids while preserving the uterus), and endometrial ablation (destruction of the lining of the uterus).

Minimally invasive surgical techniques such as laparoscopy and hysteroscopy have gained popularity in recent years due to their advantages over traditional open surgeries, including smaller incisions, less postoperative pain, quicker recovery times, and reduced risk of complications.

"Drug approval" is the process by which a regulatory agency, such as the US Food and Drug Administration (FDA), grants formal authorization for a pharmaceutical company to market and sell a drug for a specific medical condition. The approval process is based on rigorous evaluation of clinical trial data to ensure that the drug is safe and effective for its intended use.

The FDA's approval process typically involves several stages, including preclinical testing in the lab and animal studies, followed by three phases of clinical trials in human subjects. The first phase tests the safety of the drug in a small group of healthy volunteers, while the second and third phases test the drug's efficacy and side effects in larger groups of patients with the medical condition for which the drug is intended.

If the results of these studies demonstrate that the drug is safe and effective, the pharmaceutical company can submit a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA for review. The application includes data from the clinical trials, as well as information about the manufacturing process, labeling, and proposed use of the drug.

The FDA reviews the application and may seek input from independent experts before making a decision on whether to approve the drug. If approved, the drug can be marketed and sold to patients with the medical condition for which it was approved. The FDA continues to monitor the safety and efficacy of approved drugs after they reach the market to ensure that they remain safe and effective for their intended use.

Laparoscopy is a surgical procedure that involves the insertion of a laparoscope, which is a thin tube with a light and camera attached to it, through small incisions in the abdomen. This allows the surgeon to view the internal organs without making large incisions. It's commonly used to diagnose and treat various conditions such as endometriosis, ovarian cysts, infertility, and appendicitis. The advantages of laparoscopy over traditional open surgery include smaller incisions, less pain, shorter hospital stays, and quicker recovery times.

Genital neoplasms in females refer to abnormal growths or tumors that occur in the female reproductive organs. These can be benign (non-cancerous) or malignant (cancerous). The most common types of female genital neoplasms are:

1. Cervical cancer: This is a malignancy that arises from the cells lining the cervix, usually caused by human papillomavirus (HPV) infection.
2. Uterine cancer: Also known as endometrial cancer, this type of female genital neoplasm originates in the lining of the uterus (endometrium).
3. Ovarian cancer: This is a malignancy that develops from the cells in the ovaries, which can be difficult to detect at an early stage due to its location and lack of symptoms.
4. Vulvar cancer: A rare type of female genital neoplasm that affects the external female genital area (vulva).
5. Vaginal cancer: This is a malignancy that occurs in the vagina, often caused by HPV infection.
6. Gestational trophoblastic neoplasia: A rare group of tumors that develop from placental tissue and can occur during or after pregnancy.

Regular screening and early detection are crucial for successful treatment and management of female genital neoplasms.

A vaginal fistula is an abnormal opening or connection between the vagina and another organ, such as the bladder (resulting in a vesicovaginal fistula), the rectum (resulting in a rectovaginal fistula), or the colon (resulting in a colovaginal fistula). This condition can lead to various complications, including chronic urinary or fecal incontinence, infection, and difficulty with sexual intercourse.

Vaginal fistulas are often caused by obstetric trauma, such as prolonged labor, or may be the result of surgery, radiation therapy, injury, or infection. Symptoms can vary depending on the size and location of the fistula but typically include abnormal discharge, pain, and foul-smelling odor. Treatment usually involves surgical repair of the fistula, although smaller fistulas may sometimes heal on their own with proper care and management.

The United States Food and Drug Administration (FDA) is a federal government agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our country's food supply, cosmetics, and products that emit radiation. The FDA also provides guidance on the proper use of these products, and enforces laws and regulations related to them. It is part of the Department of Health and Human Services (HHS).

Alphaprodine is a synthetic opioid medication that is primarily used for its analgesic (pain-relieving) effects. It belongs to the class of drugs known as narcotic analgesics, which work by binding to specific receptors in the brain and spinal cord to reduce the perception of pain.

Alphaprodine is a controlled substance due to its potential for abuse and dependence. It can produce euphoria, drowsiness, respiratory depression, and constipation, among other side effects. Long-term use or misuse of alphaprodine can lead to physical dependence and withdrawal symptoms upon discontinuation.

Alphaprodine is not commonly used in clinical practice today due to the availability of safer and more effective pain medications. It is also not available as a generic medication, and only one branded formulation (Nisentil) was approved by the FDA for use in the United States, but it has been discontinued from the market.

... is a rare condition seen exclusively in women in which leiomyomata, benign smooth muscle tumors, are ... Dal Cin, P.; Quade, B.; Neskey, D.; Kleinman, M.; Weremowicz, S.; Morton, C. (2003). "Intravenous leiomyomatosis is ... "Intravenous leiomyomatosis with intracardiac extension: a single-institution experience". American Journal of Obstetrics and ...
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) or Reed's syndrome is rare autosomal dominant disorder associated ... "Hereditary Leiomyomatosis and Renal Cell Carcinoma". NORD (National Organization for Rare Disorders). Retrieved 8 April 2019. ... It predisposes for renal cell cancer, an association denominated hereditary leiomyomatosis and renal cell cancer, and it is ... Reed syndrome and Hereditary leiomyomatosis and renal cell cancer at the Genetic and Rare Diseases Information Center (GARD) ( ...
PDHA1 Leiomyomatosis and renal cell cancer; 605839; FH Leiomyomatosis, diffuse, with Alport syndrome; 308940; COL4A6 LEOPARD ...
There have been reports of the finding of occurrence of endometriosis in leiomyomatosis peritonealis disseminata. More than 15 ... Kuo T, London SN, Dish TV (1980). Endometriosis occurring in leiomyomatosis peritonealis disseminata. Am J Surg Pathol 4:197- ... Rohling MB, Kao KJ, Woodard BH (1981). Endomyometriosis: Possible association with leiomyomatosis disseminata and endometriosis ...
Hereditary leiomyomatosis and renal cell cancer Founder effect "Fumarase deficiency , Genetic and Rare Diseases Information ... hereditary leiomyomatosis and renal cell cancer. Fumarase deficiency is one of the few known deficiencies of the Krebs cycle or ... "Hereditary Leiomyomatosis and Renal Cell Cancer". GeneReviews. Seattle WA: University of Washington. PMID 20301430. (Articles ...
Butnor KJ, Burchette JL, Robboy SJ (July 1999). "Progesterone receptor activity in leiomyomatosis peritonealis disseminata". ...
List of cutaneous conditions "Hereditary leiomyomatosis and renal cell cancer , Genetic and Rare Diseases Information Center ( ... Sometimes associated with uterine leiomyomas (a combination known as multiple cutaneous and uterine leiomyomatosis, MCUL), ... these lesions may also be a manifestation of the hereditary leiomyomatosis and renal cell cancer syndrome. ...
Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis". J. Biol. Chem. 268 (35): 26033-6. doi:10.1016/ ...
Tolvanen J, Uimari O, Ryynänen M, Aaltonen LA, Vahteristo P (2012). "Strong family history of uterine leiomyomatosis warrants ... 2003). "Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North ... "Morphologic Features of Uterine Leiomyomas Associated with Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome". The ... halos should alert the pathologist to investigate the possibility of the extremely rare hereditary leiomyomatosis and renal ...
Intravascular leiomyomatosis is a benign neoplasm that extends through the veins; angioleiomyoma is a benign neoplasm of the ...
... -Leiomyomatosis Peritoneal): A Hardly Known Entity". Case Reports in Obstetrics and Gynecology. 2012: 1-3. doi: ...
Diffuse leiomyomatosis of the oesophagus and tracheobronchial tree has been reported in some families with Alport syndrome. ... Leiomyomatosis is confirmed by computed tomography (CT) scanning or magnetic resonance imaging (MRI). Aortic dissection has ...
... then leiomyomatosis and renal cell carcinoma/Reed's syndrome (multiple cutaneous and uterine leiomyomatosis) could result. ... These include benign mesenchymal tumors of the uterus, leiomyomatosis and renal cell carcinoma, and fumarase deficiency. ...
Deletions in the alpha 5 gene that extend into the alpha 6 gene result in diffuse leiomyomatosis accompanying the X-linked ... which is mutated in Alport syndrome-associated leiomyomatosis". Genomics. 33 (3): 473-9. doi:10.1006/geno.1996.0222. PMID ...
Fulcher, A. S.; Szucs, R. A. (November 1998). "Leiomyomatosis peritonealis disseminata complicated by sarcomatous ...
Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis ...
In some cases the renal cell carcinoma may be a manifestation of an undiagnosed hereditary leiomyomatosis and renal cell cancer ...
... whereas those with hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome have an increased risk of type 2 PRCC. ... type 2 PRCC is the pathological subtype that is most commonly associated with hereditary leiomyomatosis and renal cell ... locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis ...
... and diffuse peritoneal leiomyomatosis. These diagnoses should be considered in patients with suspected omental caking and a ...
... leiomyomatosis cutis et uteri, multiple leiomyomatosis, Reed's syndrome) Multiple cutaneous leiomyoma (pilar leiomyoma) Neural ... Multinucleate cell angiohistocytoma Multiple cutaneous and uterine leiomyomatosis syndrome ( ...
Concern Chemicals Reforms promulgated by the National Industrial Chemicals Notification and Assessment Scheme Leiomyomatosis ...
... leiomyomatosis MeSH C04.557.450.590.455 - leiomyosarcoma MeSH C04.557.450.590.540 - myoma MeSH C04.557.450.590.540.700 - ...
... syndrome Hepatorenal syndrome Hereditary breast-ovarian cancer syndrome Hereditary hyperbilirubinemia Hereditary leiomyomatosis ...
... hereditary leiomyomatosis, Birt-Hogg-Dube syndrome, hyperparathyroidism-jaw tumor syndrome, familial papillary thyroid ... Hybrid oncocytoma/chromophobe renal cell carcinoma Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) Laboratory tests ...
... hereditary leiomyomatosis renal cell cancer (LRCC), hereditary papillary renal cell cancer, hereditary paraganglioma- ...
... and hereditary leiomyomatosis and renal cell cancer syndrome. They are differentiated with examination of the tumors' histology ...
Fibromyoma Leiomyofibroma Plexiform leiomyoma Lipoleiomyoma M8890/1 Leiomyomatosis, NOS Intravascular leiomyomatosis M8890/3 ...
... hereditary leiomyomatosis and renal cell cancer syndrome - hereditary mutation - hereditary nonpolyposis colon cancer - ...
French Canadian type Leiner disease Leiomyoma Leiomyomatosis familial Leiomyomatosis of oesophagus cataract hematuria ...
Dieterich's disease Diethylstilbestrol antenatal infection Diffuse idiopathic skeletal hyperostosis Diffuse leiomyomatosis with ...
Find symptoms and other information about Hereditary leiomyomatosis and renal cell cancer. ... Familial leiomyomatosis and renal cell cancer; Familial leiomyomatosis cutis et uteri; Familial leiomyomatosis with renal ... Reed syndromeFamilial leiomyomatosis and renal cell cancer; Familial leiomyomatosis cutis et uteri; Familial leiomyomatosis ... Hereditary leiomyomatosis and renal cell cancer is a genetic disease. This means that one or more genes have differences that ...
Intravenous leiomyomatosis is a rare condition seen exclusively in women in which leiomyomata, benign smooth muscle tumors, are ... Dal Cin, P.; Quade, B.; Neskey, D.; Kleinman, M.; Weremowicz, S.; Morton, C. (2003). "Intravenous leiomyomatosis is ... "Intravenous leiomyomatosis with intracardiac extension: a single-institution experience". American Journal of Obstetrics and ...
This case study documents a patient with intravenous leiomyomatosis, a rare neoplasm thought to be due to growth of a uterine ...
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a genetic disease that predisposes individuals to the development of ... Abbreviations: CoA, coenzyme A; FH, fumarate hydratase gene; HLRCC, hereditary leiomyomatosis and renal cell cancer; SDH, ... Abbreviations: CoA, coenzyme A; FH, fumarate hydratase gene; HLRCC, hereditary leiomyomatosis and renal cell cancer; SDH, ... Cite this: Mechanisms of Disease: Hereditary Leiomyomatosis Renal Cell Cancer -- A Distinct Form of Hereditary Kidney Cancer - ...
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder in which affected individuals tend to develop benign ... is also sometimes called multiple cutaneous leiomyomatosis (MCL) or multiple cutaneous and uterine leiomyomatosis (MCUL). ... Hereditary leiomyomatosis and renal cell cancer syndrome: An update and review. J Am Acad Dermatol. 2017 Jul;77(1):149-158. doi ... Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder in which affected individuals tend to develop benign ...
Leiomyomatosis peritonealis disseminata with sigmoid stenosis. Download Prime PubMed App to iPhone, iPad, or Android ... Diffuse uterine leiomyomatosis.. *Leiomyomatosis peritonealis disseminata. A report of two cases and review of the literature. ... Leiomyomatosis peritonealis disseminata associated with pregnancy.. *[Leiomyomatosis peritonealis disseminata. ... Leiomyomatosis peritonealis disseminata with sigmoid stenosis.. Morphol Embryol (Bucur). 1987 Oct-Dec; 33(4):269-73.ME ...
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder in which affected individuals tend to develop benign ... is also sometimes called multiple cutaneous leiomyomatosis (MCL) or multiple cutaneous and uterine leiomyomatosis (MCUL). ... Hereditary leiomyomatosis and renal cell cancer syndrome: An update and review. J Am Acad Dermatol. 2017 Jul;77(1):149-158. doi ... Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder in which affected individuals tend to develop benign ...
8. Quade BJ, Dal Cin P, Neskey DM, et al: IV leiomyomatosis: molecular and cytogenetic analysis of a case.Mod Pathol 15:351-356 ... Dal Cin P, Quade BJ, Neskey DM, et al: IV leiomyomatosis is characterizedby a der(14)t(12;14)(q15;q24). Genes Chromosomes ... 5. Clement PB, Young RH, Scully RE: Intravenous leiomyomatosis of the uterus. A clinicopathologicalanalysis of 16 cases with ... 9. Canzonieri V, DAmore ES, Bartoloni G, et al: Leiomyomatosis with vascular invasion. A unifiedpathogenesis regarding ...
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal-dominant hereditary syndrome, which is caused by ... Hereditary leiomyomatosis and renal cell carcinoma Laura S Schmidt et al. Int J Nephrol Renovasc Dis. 2014. . ... Hereditary leiomyomatosis and renal cell carcinoma Laura S Schmidt 1 , W Marston Linehan 2 ... Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research. Ooi A. Ooi A. Semin Cancer Biol. 2020 Apr;61: ...
Role of ultra-high b-value DWI in the imaging of hereditary leiomyomatosis and renal cell carcinoma (HLRCC) Aditi Chaurasia 1 ... Role of ultra-high b-value DWI in the imaging of hereditary leiomyomatosis and renal cell carcinoma (HLRCC) Aditi Chaurasia et ... Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings. Paschall AK, Nikpanah M, ... Purpose: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is associated with an aggressive form of renal ...
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare autosomal dominant condition characterized by the ... of Fumarate Hydratase Enzyme Expression and Activity in Clinically Positive but Genetically Undefined Hereditary Leiomyomatosis ...
An unusual cause of pseudoachalasia: The Alport syndrome-diffuse leiomyomatosis association. Rita G. Sousa, Pedro C. Figueiredo ... An unusual cause of pseudoachalasia : The Alport syndrome-diffuse leiomyomatosis association. In: European Journal of ... An unusual cause of pseudoachalasia: The Alport syndrome-diffuse leiomyomatosis association. European Journal of ... Rarely, AS coexists with diffuse leiomyomatosis, a benign proliferation of smooth muscle in the gastrointestinal tract, mostly ...
... In Memory of Andrew Lee Posted on June 13th, 2019. by Dr. Francis Collins ... Hereditary Leiomyomatosis and Renal Cell Cancer (National Library of Medicine/NIH) Kidney (Renal Cell) Cancer (National Cancer ... Hereditary Leiomyomatosis and Renal Cell Cance, HLRCC, Isaac Barchus, kidney cancer, NIH Clinical Center, NIH Clinical Center ... a rare type called Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). There is no known cure for HLRCC, and doctors ...
... On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a ...
Leiomyomatosis. All patients with Alport syndrome diffuse leiomyomatosis complex have been found to have deletions that span ... Diffuse leiomyomatosis of the esophagus and tracheobronchial tree has been reported in some families with Alport syndrome. ... ends of the COL4A5 and COL4A6 genes is associated with a rare combination of XLAS and diffuse leiomyomatosis of the esophagus, ...
Leiomyomatosis. All patients with Alport syndrome diffuse leiomyomatosis complex have been found to have deletions that span ... Diffuse leiomyomatosis of the esophagus and tracheobronchial tree has been reported in some families with Alport syndrome. ... ends of the COL4A5 and COL4A6 genes is associated with a rare combination of XLAS and diffuse leiomyomatosis of the esophagus, ...
The disease is caused by mutations in the FH gene.… Hereditary Leiomyomatosis and Renal Cell Cancer: Read more about Symptoms, ... hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder of genetic origin that predisposes for the development of ... Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a cancer susceptibility syndrome caused by mutations in the FH gene ... Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma. Nat Clin Pract ...
We have optimized all our processes to accept a wide range of samples, always adapting to each case ...
Leiomyomatosis peritonealis disseminata (LPD) is a rare disorder characterized by multiple subperitoneal benign smooth muscle ... Leiomyomatosis peritonealis disseminata (LPD) is a rare disorder characterized by multiple subperitoneal benign smooth muscle ... Leiomyomatosis Peritonealis Disseminata: MRI Features Before and After Treatment with GnRH Agonist ...
OR leiomyomatosis [tw]. OR leiomyosarcoma [tw]. OR leiomyosarcomas [tw]. OR leukaemia [tw]. OR leukaemias [tw]. OR leukemia [tw ...
Uterine intravenous leiomyomatosis with cardiac extension: Imaging characteristics and lit Uterine intravenous leiomyomatosis ... Intravenous leiomyomatosis (IVL), showing unusual growth patterns of uterine leiomyoma, is a rare neoplasm characterized by ...
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome predisposes patients to uterine and cutaneous leiomyomas ( ... Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome predisposes patients to uterine and cutaneous leiomyomas ( ... Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome- ... Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome- ...
Leiomyomatosis of the esophagus: experience over a decade. J Gastrointest Surg. 2009 Feb. 13(2):206-11. [QxMD MEDLINE Link]. ... Leiomyomatosis is a variation of leiomyoma in which multiple leiomyomas develop throughout the length of the esophagus and can ... Esophageal leiomyomatosis -- an unusual cause of pseudoachalasia. Can J Gastroenterol. 2008 Feb. 22(2):187-9. [QxMD MEDLINE ... Multimodality diagnostic imaging of diffuse esophageal leiomyomatosis. J Comput Assist Tomogr. 2006 Jan-Feb. 30(1):100-4. [QxMD ...
A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell ...
In a very small number of patients with a condition called hereditary leiomyomatosis and renal cell cancer (HLRCC), the ... Pithukpakorn, M., & Toro, J.R. (2015). Hereditary leiomyomatosis and renal cell cancer. Retrieved May 3, 2018, from https://www ...
Multiple cutaneous and uterine leiomyomatosis in a 36-year-old female, and discussion of hereditary leiomyomatosis and renal ... From gene to disease; cutaneous leiomyomatosis].. Badeloe S; van Geel M; van Steensel MA; Steijlen PM; Poblete-Gutiérrez P; ... Cutaneous leiomyomas: a clinical marker of risk for hereditary leiomyomatosis and renal cell cancer.. Stewart L; Glenn G; Toro ... The syndrome of hereditary leiomyomatosis and renal cell cancer (HLRCC): The clinical features of an individual with a fumarate ...
Hereditary leiomyomatosis and renal cell cancer. *Hereditary leiomyomatosis and renal cell carcinoma, see Hereditary ...
Title: Cyst(e)inase-Rapamycin Combination Induces Ferroptosis in Both In Vitro and In Vivo Models of Hereditary Leiomyomatosis ... Abstract: Renal cell carcinomas associated with hereditary leiomyomatosis and renal cell cancer (HLRCC) are notoriously ... Leiomyomatosis; Male; Mice; Neoplastic Syndromes, Hereditary; Sirolimus/pharmacology; Skin Neoplasms; Uterine Neoplasms ...
  • An exceptional case of Leiomyomatosis peritonealis disseminata which occurred in a perimenopausal woman was mistaken for ovarian malignancy at laparotomy as it had extensive involvement of the pelvic peritoneum without a trace of leiomyoma in uterus and cervix. (southampton.ac.uk)
  • Leiomyomatosis peritonealis disseminata (LPD) is an exceedingly rare, usually benign condition that clinically simulates a disseminated malignancy. (elsevierpure.com)
  • 3. Taubert HD, Wissner SE, Haskins AL (1965) Leiomyomatosis peritonealis disseminata: an unusual complication of genital leiomyomata. (ijrr.com)
  • Al-Talib A, Tulandi T. Pathophysiology and possible iatrogenic cause of leiomyomatosis peritonealis disseminata. (mdedge.com)
  • Bogusiewicz M, Rosinska-Bogusiewicz K, Walczyna B, Drop A, Rechberger T. Leiomyomatosis peritonealis disseminata with formation of endometrial cysts within tumors arising after supracervical laparoscopic hysterectomy. (mdedge.com)
  • Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Reed's Syndrome is one of several rare familial syndromes involving kidney cancer and is caused by mutations in the Fumarate Hydratase (FH) Gene. (blogspot.com)
  • and uterine leiomyomata multiple cutaneous (MCUL) (See Hereditary leiomyomatosis and renal cancer). (ivami.com)
  • Her medical team soon discovered she had hereditary leiomyomatosis as well as renal cell cancer, otherwise known as HLRCC. (childrensinn.org)
  • Andrew was 19, just finishing his freshman year of college, when he received a devastating diagnosis: stage 4 kidney cancer, a rare type called Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). (nih.gov)
  • DTC is a non-profit 501 (c3) established to help raise awareness and provide funding for the research of rare kidney cancers like Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) in children and young adults. (carlisleevents.com)
  • More than 70 mutations in the FH gene that cause hereditary leiomyomatosis and renal cell cancer (HLRCC) have been reported. (encyclopedia.pub)
  • Genetic and functional analyses of FH mutations in multiplecutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer,and fumarate hydratase deficiency. (encyclopedia.pub)
  • Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patients. (uchicago.edu)
  • Diffuse peritoneal leiomyomatosis. (southampton.ac.uk)
  • Minimally invasive therapy of peritoneal leiomyomatosis. (southampton.ac.uk)
  • What is Disseminated peritoneal leiomyomatosis? (rarediseaseshealthcenter.com)
  • Disseminated peritoneal leiomyomatosis (DPL) is a rare condition in which benign (non-cancerous) smooth muscle tumors called leiomyomas grow in the peritoneal cavity, which is the space in the abdomen that contains the intestines, stomach, and other organs. (rarediseaseshealthcenter.com)
  • What are the symptoms of Disseminated peritoneal leiomyomatosis? (rarediseaseshealthcenter.com)
  • The exact cause of disseminated peritoneal leiomyomatosis is unknown. (rarediseaseshealthcenter.com)
  • Additionally, some studies suggest that certain medications, such as tamoxifen, may increase the risk of developing disseminated peritoneal leiomyomatosis. (rarediseaseshealthcenter.com)
  • What are the treatments for Disseminated peritoneal leiomyomatosis? (rarediseaseshealthcenter.com)
  • 1. Surgery: Surgery is the primary treatment for disseminated peritoneal leiomyomatosis. (rarediseaseshealthcenter.com)
  • 5. Clinical Trials: Clinical trials are ongoing to evaluate new treatments for disseminated peritoneal leiomyomatosis. (rarediseaseshealthcenter.com)
  • Is there a cure/medications for Disseminated peritoneal leiomyomatosis? (rarediseaseshealthcenter.com)
  • At this time, there is no known cure for Disseminated Peritoneal Leiomyomatosis (DPL). (rarediseaseshealthcenter.com)
  • Disseminated Peritoneal Leiomyomatosis (DPL) is a rare benign illness characterized by numerous smooth muscle nodules over the peritoneal surface of the abdomen and pelvis. (ijrr.com)
  • 2022) Disseminated peritoneal leiomyomatosis as an incidental finding: A case report. (ijrr.com)
  • 2020)Disseminated peritoneal leiomyomatosis: A case report. (ijrr.com)
  • 2016) Disseminated peritoneal leiomyomatosis status post laparoscopic hysterectomy with morcellation. (ijrr.com)
  • 2021)Disseminated peritoneal leiomyomatosis with uterine smooth muscle tumors of uncertain malignant potential after morcellator. (ijrr.com)
  • 8. Demir MK(2007) Disseminated peritoneal leiomyomatosis: Magnetic resonance imaging and differential diagnosis. (ijrr.com)
  • 9. Soni S, Pareek P, Narayan S(2020)Disseminated peritoneal leiomyomatosis: an unusual presentation of intra-abdominal lesion mimicking disseminated malignancy. (ijrr.com)
  • 2021) Disseminated peritoneal leiomyomatosis: a case report and review of the literature. (ijrr.com)
  • 2019)Disseminated peritoneal leiomyomatosis following laparoscopic myomectomy: a case report. (ijrr.com)
  • Ye D, Yin H, Geng C. PET/CT Imaging of disseminated peritoneal leiomyomatosis: Cases reports. (ijrr.com)
  • Takeda A, Mori M, Sakai K, Misui T, Nakamura H. Parasitic peritoneal leiomyomatosis diagnosed 6 years after laparoscopic myomectomy with electric tissue morcellation: Report of a case and review of the literature. (mdedge.com)
  • A case of disseminated peritoneal leiomyomatosis developing after laparoscope-assisted myomectomy. (mdedge.com)
  • Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma. (mdedge.com)
  • 5. Coskun A, Ozdemir O, Vardar MA, Kiran G, Arikan D, Ersoz C. A case with diffuse uterine leiomyomatosis and review of the literature. (southampton.ac.uk)
  • Diffuse leiomyomatosis of the esophagus and tracheobronchial tree has been reported in some families with Alport syndrome. (medscape.com)
  • 4, 5 Until recently, the only known contiguous gene syndrome involving the COL4A5 gene was Alport syndrome and diffuse leiomyomatosis (ATS-DL, OMIM 308940), 6- 9 in which the deletion extends towards the centromere to include the first two exons of the adjacent COL4A6 gene. (bmj.com)
  • Multiple cutaneous and uterine leiomyomatosis (Reed's syndrome). (uchicago.edu)
  • Intravenous leiomyomatosis is a rare condition seen exclusively in women in which leiomyomata, benign smooth muscle tumors, are found in veins. (wikipedia.org)
  • Typically solitary, multiple tumors (leiomyomatosis) are occasionally reported. (ac.ir)
  • In this study, we report a rare case of esophageal leiomyomatosis treated by esophagectomy. (ac.ir)
  • Leiomyomatosis peritonealis disseminate and subcutaneous myoma-a rare complication of laparoscopic myomectomy. (mdedge.com)
  • This is the first reported case of leiomyomatosis secondary to a pathogenic SUFU variant in an infant and may represent an early, atypical presentation of Gorlin syndrome. (stanford.edu)
  • METHODS: 60 women were studied (30 with and 30 without uterine leiomyomatosis). (bvsalud.org)
  • OBJECTIVE: To determine the differences of hormona anti-mülleriana levels in women with and without uterine leiomyomatosis. (bvsalud.org)
  • CONCLUSIONS: Women with leiomyomatosis had lower hormona antimülleriana levels. (bvsalud.org)
  • BACKGROUND: The etiology of uterine leiomyomatosis is multifactorial and it is unknown if a relation between anti-Müllerian hormone (hormona anti-mülleriana) and uterine leiomyomatosis exists. (bvsalud.org)
  • Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a condition that causes benign tumors of smooth muscle tissue in the skin (cutaneous leiomyomas) and in the uterus in females (uterine leiomyomas, or fibroids). (nih.gov)
  • When Do Symptoms of Hereditary leiomyomatosis and renal cell cancer Begin? (nih.gov)
  • Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal-dominant hereditary syndrome, which is caused by germline mutations in the FH gene that encodes the tricarboxylic acid cycle enzyme fumarate hydratase (FH). (nih.gov)
  • Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is associated with an aggressive form of renal cell carcinoma with high risk of metastasis, even in small primary tumors with unequivocal imaging findings. (nih.gov)
  • Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare autosomal dominant condition characterized by the development of cutaneous and uterine leiomyomas. (nih.gov)
  • Andrew was 19, just finishing his freshman year of college, when he received a devastating diagnosis: stage 4 kidney cancer, a rare type called Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). (nih.gov)
  • It predisposes for renal cell cancer, an association denominated hereditary leiomyomatosis and renal cell cancer , and it is also associated with increased risk of uterine leiomyosarcoma. (findzebra.com)
  • As the name suggests , hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder of genetic origin that predisposes for the development of leiomyomas and malignant neoplasms of the kidney. (symptoma.com)
  • In a very small number of patients with a condition called hereditary leiomyomatosis and renal cell cancer (HLRCC), the fibroids are linked to kidney cancer. (nih.gov)
  • 25. Cutaneous leiomyomas: a clinical marker of risk for hereditary leiomyomatosis and renal cell cancer. (nih.gov)
  • 26. Multiple cutaneous and uterine leiomyomatosis in a 36-year-old female, and discussion of hereditary leiomyomatosis and renal cell carcinoma. (nih.gov)
  • 33. The syndrome of hereditary leiomyomatosis and renal cell cancer (HLRCC): The clinical features of an individual with a fumarate hydratase gene mutation. (nih.gov)
  • 38. Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome. (nih.gov)
  • Cyst(e)inase-Rapamycin Combination Induces Ferroptosis in Both In Vitro and In Vivo Models of Hereditary Leiomyomatosis and Renal Cell Cancer. (nih.gov)
  • Renal cell carcinomas associated with hereditary leiomyomatosis and renal cell cancer (HLRCC) are notoriously aggressive and represent the leading cause of death among patients with HLRCC. (nih.gov)
  • A cornerstone of the progress that has popularized nephron-sparing surgery is greater knowledge of the molecular biology of renal cancers facilitated largely by the study of hereditary renal cancer syndromes, including von Hippel-Lindau (VHL), hereditary PRC (HPRC), Birt-Hogg-Dubé, and hereditary leiomyomatosis and renal cell cancer ( 2, 3 ). (aacrjournals.org)
  • Intravenous leiomyomatosis is a rare condition seen exclusively in women in which leiomyomata, benign smooth muscle tumors, are found in veins. (wikipedia.org)
  • Uterine intravenous leiomyomatosis with cardiac extension: Imaging characteristics and literature review. (bvsalud.org)
  • Intravenous leiomyomatosis (IVL), showing unusual growth patterns of uterine leiomyoma , is a rare neoplasm characterized by intravascular proliferation of a histologically benign-looking smooth muscle cell tumor mass, but not invading the tissue . (bvsalud.org)
  • Rarely, AS coexists with diffuse leiomyomatosis, a benign proliferation of smooth muscle in the gastrointestinal tract, mostly of the oesophagus, but also of the tracheobronchial tree and the female genital tract. (unl.pt)
  • Diffuse leiomyomatosis of the esophagus and tracheobronchial tree has been reported in some families with Alport syndrome. (medscape.com)
  • The acronym ASDL is commonly used to refer to Alport syndrome with diffuse leiomyomatosis . (alportsyndrome.org)
  • This disorder, especially if it appears in individuals or families without renal cell cancer, is also sometimes called multiple cutaneous leiomyomatosis (MCL) or multiple cutaneous and uterine leiomyomatosis (MCUL). (medlineplus.gov)
  • Esophageal leiomyomatosis -- an unusual cause of pseudoachalasia. (medscape.com)
  • Typedefs only)") (termFormat EnglishLanguage MPATH--396 "osteoma") (subclass MPATH--76 MPATH--56) (termFormat EnglishLanguage MPATH--171 "squamous metaplasia") (termFormat EnglishLanguage MPATH--143 "microglandular hyperplasia") (subclass MPATH--139 MPATH--138) (termFormat EnglishLanguage MPATH--424 "intravascular leiomyomatosis") (termFormat EnglishLanguage MPATH--379 "odontogenic tumor") (mo-remark "Contract number QLRI-CT-1999-00320. (ontologyportal.org)
  • Leiomyomatosis peritonealis disseminata (LPD) is a rare disorder characterized by multiple subperitoneal benign smooth muscle nodules. (ejgm.org)
  • Leiomyomatosis is a variation of leiomyoma in which multiple leiomyomas develop throughout the length of the esophagus and can be associated with Alport's syndrome. (medscape.com)
  • Leiomyomatosis of the esophagus: experience over a decade. (medscape.com)